|
1
|
Jameson JL and Longo DL: Precision
medicine-personalized, problematic, and promising. N Engl J Med.
372:2229–2234. 2015.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Jordan VC: Fourteenth gaddum memorial
lecture. A current view of tamoxifen for the treatment and
prevention of breast cancer. Br J Pharmacol. 110:507–517.
1993.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Buchdunger E, Zimmermann J, Mett H, Meyer
T, Müller M, Druker BJ and Lydon NB: Inhibition of the Abl
protein-tyrosine kinase in vitro and in vivo by a
2-phenylaminopyrimidine derivative. Cancer Res. 56:100–104.
1996.PubMed/NCBI
|
|
4
|
Andre F, Mardis E, Salm M, Soria JC, Siu
LL and Swanton C: Prioritizing targets for precision cancer
medicine. Ann Oncol. 25:2295–2303. 2014.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Maxam MA and Gilbert W: A new method for
sequencing DNA. Proc Natl Acad Sci USA. 74:560–564. 1977.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Heather JM and Chain B: The sequence of
sequencers: The history of sequencing DNA. Genomics. 107:1–8.
2016.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Mardis ER: Next-generation DNA sequencing
methods. Annu Rev Genomics Hum Genet. 9:387–402. 2008.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Shendure J and Ji H: Next-generation DNA
sequencing. Nat Biotechnol. 26:1135–1145. 2008.PubMed/NCBI View
Article : Google Scholar
|
|
9
|
Behjati S and Tarpey PS: What is next
generation sequencing? Arch Dis Child Educ Pract Ed. 98:236–238.
2013.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Marabelle A, Le DT, Ascierto PA, Di
Giacomo AM, De Jesus-Acosta A, Delord JP, Geva R, Gottfried M,
Penel N, Hansen AR, et al: Efficacy of pembrolizumab in patients
with noncolorectal high microsatellite instability/mismatch
repair-deficient cancer: Results from the phase II KEYNOTE-158
study. J Clin Oncol. 38:1–10. 2020.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Looney AM, Nawaz K and Webster RM:
Tumour-agnostic therapies. Nat Rev Drug Discov. 19:383–384.
2020.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Park JJH, Hsu G, Siden EG, Thorlund K and
Mills EJ: An overview of precision oncology basket and umbrella
trials for clinicians. CA Cancer J Clin. 70:125–137.
2020.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Goodwin S, McPherson JD and McCombie WR:
Coming of age: Ten years of next-generation sequencing
technologies. Nat Rev Genet. 17:333–351. 2016.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Liu Z, Zhu L, Roberts R and Tong W: Toward
clinical implementation of next-generation sequencing-based genetic
testing in rare diseases: Where are we? Trends Genet. 35:852–867.
2019.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Gatta G, Capocaccia R, Botta L, Mallone S,
De Angelis R, Ardanaz E, Comber H, Dimitrova N, Leinonen MK,
Siesling S, et al: Burden and centralised treatment in Europe of
rare tumours: Results of RARECAREnet-a population-based study.
Lancet Oncol. 18:1022–1039. 2017.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Subbiah IM, Tsimberidou A, Subbiah V,
Janku F, Roy-Chowdhuri S and Hong DS: Next generation sequencing of
carcinoma of unknown primary reveals novel combinatorial strategies
in a heterogeneous mutational landscape. Oncoscience. 4:47–56.
2017.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Frampton GM, Fichtenholtz A, Otto GA, Wang
K, Downing SR, He J, Schnall-Levin M, White J, Sanford EM, An P, et
al: Development and validation of a clinical cancer genomic
profiling test based on massively parallel DNA sequencing. Nat
Biotechnol. 31:1023–1031. 2013.PubMed/NCBI View
Article : Google Scholar
|
|
18
|
Alegretti M, Fabi A, Buglioni S, Martayan
A, Conti L, Pescarmona E, Ciliberto G and Giacomini P: Tearing down
the walls: FDA approves next generation sequencing (NGS) assays for
actionable cancer genomic aberrations. J Exp Clin Cancer Res.
37(47)2018.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Matthijs G, Souche E, Alders M, Corveleyn
A, Eck S, Feenstra I, Race V, Sistermans E, Sturm M, Weiss M, et
al: Guidelines for diagnostic next-generation sequencing. Eur J Hum
Genet. 24(1515)2016.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Marquart J, Chen EY and Prasad V:
Estimation of the percentage of US patients with cancer who benefit
from genome-driven oncology. JAMA Oncol. 4:1093–1098.
2018.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Schwartzberg L, Kim ES, Liu D and Schrag
D: Precision oncology: Who, how, what, when, and when not? Am Soc
Clin Oncol Educ Book. 37:160–169. 2017.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Colomer R, Mondejar R, Romero-Laorden N,
Alfranca A, Sanchez-Madrid F and Quintela-Fandino M: When should we
order a next generation sequencing test in a patient with cancer?
EClinicalMedicine. 25(100487)2020.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Binder C, Matthes KL, Korol D, Rohrmann S
and Moch H: Cancer of unknown primary-Epidemiological trends and
relevance of comprehensive genomic profiling. Cancer Med.
7:4814–4824. 2018.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Subbiah V, Solit DB, Chan TA and Kurzrock
R: The FDA approval of pembrolizumab for adult and pediatric
patients with tumor mutational burden (TMB) ≥10: A decision
centered on empowering patients and their physicians. Ann Oncol.
31:1115–1118. 2020.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Marabelle A, Fakih M, Lopez J, Shah M,
Shapira-Frommer R, Nakagawa K, Chung HC, Kindler HL, Lopez-Martin
JA, Miller WH Jr, et al: Association of tumour mutational burden
with outcomes in patients with advanced solid tumours treated with
pembrolizumab: Prospective biomarker analysis of the multicohort,
open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 21:1353–1365.
2020.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Sunami K, Ichikawa H, Kubo T, Kato M,
Fujiwara Y, Shimomura A, Koyama T, Kakishima H, Kitami M,
Matsushita H, et al: Feasibility and utility of a panel testing for
114 cancer-associated genes in a clinical setting: A hospital-based
study. Cancer Sci. 110:1480–1490. 2019.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Mosele F, Remon J, Mateo J, Westphalen CB,
Barlesi F, Lolkema MP, Normanno N, Scarpa A, Robson M,
Meric-Bernstam F, et al: Recommendations for the use of
next-generation sequencing (NGS) for patients with metastatic
cancers: A report from the ESMO precision medicine working group.
Ann Oncol. 31:1491–1505. 2020.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Mateo J, Chakravarty D, Dienstmann R,
Jezdic S, Gonzalez-Perez A, Lopez-Bigas N, Ng CKY, Bedard PL,
Tortora G, Douillard JY, et al: A framework to rank genomic
alterations as targets for cancer precision medicine: The ESMO
scale for clinical actionability of molecular targets (ESCAT). Ann
Oncol. 29:1895–1902. 2018.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Hotta K, Aoe K, Kozuki T, Ohashi K,
Ninomiya K, Ichihara E, Kubo T, Ninomiya T, Chikamori K, Harada D,
et al: A phase II study of trastuzumab emtansine in HER2-positive
non-small cell lung cancer. J Thorac Oncol. 13:273–279.
2018.PubMed/NCBI View Article : Google Scholar
|
